Introduction
Since the introduction of prostate-speci®c antigen (PSA) as a tumor marker, PSA-detected cancers have become increasingly more common while tumors detected by digital rectal examination (DRE) occur less frequently. Due to widespread PSA screening, prostate cancer is being diagnosed at an earlier stage and has resulted in an increase in the detection of organ-con®ned, curable tumors. 1 Even though clinical screening by both PSA and DRE has improved our ability for detecting pathologically organ-con®ned disease, 1 almost 50% of men believed to have organ-con®ned disease are found to have extraprostatic disease at surgery. 2 ± 4 In a study of over 1600 men undergoing radical prostatectomy for clinically localized disease, approximately 80% of clinical stage T1a tumors, 60% of T1b, 40% of stage T2a, 25% of stage T2b-T2c, and less than 10% of T3a tumors are pathologically organcon®ned. 3 A multi-institutional study comprising 4133 patients undergoing radical prostatectomy has demonstrated that 61% of PSA-detected tumors (T1c) are organcon®ned by pathologic analysis. 5 Despite our best efforts to clinically identify those men with potentially curable organ-con®ned disease, these studies suggest that clinical staging frequently results in understaging. Therefore, it is necessary to improve preoperative staging for properly selected men with locally con®ned disease who will bene®t from de®nitive local therapy (surgery or radiation therapy) since radical prostatectomy is most effective for organ or specimen-con®ned disease. 2, 3, 6 magnetic resonance imaging (MRI), and bone and soft tissue scintigraphy have had a limited role for staging due to low sensitivity and speci®city for detecting extraprostatic disease.
The Gleason score of the prostate biopsy directly correlates with ®nal pathologic stage. 4,5,7 ± 9 Tumors having Gleason scores of 8 ± 10 have a higher frequency of extraprostatic disease while tumors of low grade infrequently manifest local or distant spread. In a study of over 1600 patients, 89% of 152 men with Gleason scores 8 ± 10 had extracapsular disease and 28% had pelvic lymph node metastases. 3 Although the Gleason score alone is a signi®cant predictor of pathologic stage, it is clinically useful for the individual patient`15% of the time. 4 Predicting pathologic stage based solely on the Gleason score is of limited clinical utility since most men with localized prostate cancer have moderatelydifferentiated tumors (90% Ð Gleason score 5 ± 7).
The ability of PSA to predict organ-con®ned disease has been extensively investigated. Several studies demonstrate a correlation between PSA and pathologic stage. 4,5,7,10 ± 13 As the preoperative PSA level increases, the probability of having organ-con®ned prostate cancer linearly decreases. 5 Approximately 75% of men with a preoperative PSA level 4.0 ng/mL have organ-con®ned disease. 4 Serum PSA also directly correlates with histologic grade, 11, 13 clinical stage, 11 pathologic stage, 4,5,7,10 ± 13 and tumor volume. 8, 11, 13, 14 Although PSA shows a strong association with prostate volume and cancer density, one study has determined that PSA correlates best with cancer volume.
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Despite PSAs strong correlation with pathologic stage by univariate analysis, several limitations exist. PSA measurements can be in¯uenced by prostatic disease, urologic manipulations such as prostate biopsy, pharmacological treatment, ejaculation, the degree of tumor differentiation and the presence of BPH. It has been previously shown that higher grade tumors produce less PSA per gram of tumor despite having larger tumor volumes. 14 The interpretation of PSA levels is also in¯u-enced by the variability both in the amount of BPH 11 and the ratio of epithelial-to-stromal weight of BPH tissue. 14 4,5,7 ± 10,13,16 ± 23 Bostwick et al 9 has retrospectively analyzed several preoperative variables of over 300 untreated patients undergoing radical prostatectomy to preoperatively predict extracapsular disease. These authors have determined by multivariate analysis that PSA and percent cancer in the biopsy are the most informative independent predictors of capsular penetration and seminal vesicle invasion. In this study, the combination of PSA level, percent cancer in the biopsy, and Gleason score best predicts seminal vesicle invasion and capsular penetration. 9 Kleer et al 7 have used multivariate logistic regression analysis to retrospectively evaluate 945 patients undergoing radical retropubic prostatectomy at the Mayo Clinic. In this study, the likelihood of extraprostatic disease and lymph node involvement are directly proportional to preoperative PSA values. 7 These authors demonstrate that clinical stage and tumor grade when combined with PSA, the most signi®cant predictor of maximal extent of prostate cancer at surgery, signi®cantly improves the prediction of pathologic stage.
Several investigators suggest that information obtained from prostate biopsies can improve the ability to predict pathologic stage. 8, 21, 22 In addition to Gleason grade, the biopsy can provide information such as the number and location of the positive biopsies, percent tumor involvement of each core, and the presence or absence of perineural invasion. The number of positive biopsies 24 and percent core involvement is likely associated with tumor volume. 25 Ackerman et al 17 demonstrated the number of positive biopsies correlated with positive surgical margins. In men having 2 ± 6 positive biopsy sites, the likelihood of a positive margin was found to be 50%. Narayan et al 22 suggested that biopsy-based staging is more accurate than clinical staging since DRE is subject to interexaminer variability and underestimates tumor volume. Although biopsy location, number and extent involvement provide useful clinical information, limitations include sampling error, a lack of standardization of interpretation among pathologists, and an inability to accurately estimate true cancer volume. 26 Furthermore, biopsy-based variables are cumbersome and labor-intensive for the clinician and pathologist compared to clinical staging.
Nomograms: A clinically useful tool for predicting pathologic stage
Several investigators have derived nomograms based on multivariate analyses of pretreatment variables in an attempt to provide a clinically useful means to predict pathologic stage. These nomograms can guide clinicians to estimate the likelihood of a man having locally con®ned disease. This information may enable clinicians to better select men likely to bene®t from de®nitive local therapy. As a corollary, nomograms may help select men at risk of metastatic disease as these patients may bene®t from a staging lymphadenectomy prior to de®nitive local therapy. Furthermore, the nomogram may identify men at low risk of extracapsular disease and may avoid the associated morbidity and cost of pelvic lymphadenectomy. Oesterling et al 10 ®rst constructed a nomogram to stage patients with prostate cancer by combining serum prostatic acid phosphatase level, biopsy Gleason score, and clinical stage.
As PSA has become widely used as a tumor marker, Partin et al 4 constructed a nomogram by combining serum PSA, Gleason score, and clinical stage. This nomogram has been derived using logistic regression analysis and is based on 703 previously untreated men with clinically localized prostate cancer undergoing radical prostatectomy. Use of this nomogram at our institution has improved the percent of organ-con®ned tumors from 33% (pre-nomogram era, 1987 ± 1992) to 51% (1993 ± 1997; n 2106). Similarly, the frequency of pelvic lymph node involvement and seminal vesicle invasion also has decreased from 21 ± 10% during the same study interval. Although these statistics re¯ect clinical use of the nomogram for staging, the emergence of stage T1c tumors may also impact upon these results. 5 Although this nomogram 4 predicted organ-con®ned disease accurately, these tables have been criticized as being suboptimal for predicting high probabilities of seminal vesicle invasion and lymph node metastases when applied to a different data set of men with clinically localized prostate cancer treated with radical prostatectomy at another institution. 27 To augment the predictive power of the original nomogram 4 and establish 95% con®dence intervals for all data points, clinical information from three major urologic centers comprising over 4000 men with clinically localized prostate cancer have been combined 5 (Table 1) . Numbers within the nomogram represent percent predictive probability of the various pathological stages with 95% con®dence intervals shown in the parentheses. Using multinomial log-linear regression analysis, serum PSA level, Gleason score, and clinical stage have signi®cantly contributed to predict pathological stage. 5 The validation study has determined that 72% of the time the nomograms have correctly predicted the probability of a pathological stage to within 10%. 5 As is shown in Figure 1 , the positive predictive value increases as the estimated probability of lymph node involvement determined by the nomogram increases. The speci®city for detecting positive lymph nodes improves linearly with increasing probability in the nomogram. The sensitivity, speci®city, positive predictive value and negative predictive value for estimating organ-con®ned disease based on the nomogram are shown in Figure 2 . This nomogram has also been validated using an independent data set of patients undergoing external beam radiotherapy. 18 Pathological stage in this nomogram is based on a patient assigned to only a single category (organ-con®ned disease, capsular penetration, seminal vesicle invasion, or lymph node involvement), assuming the worst pathologic outcome. 5 For example, a man with a serum PSA of 6 ng/ mL, clinical stage T2b disease, and a biopsy Gleason score 7 has the following probabilities: 22% organ-con®ned disease, 54% established capsular penetration, 15% seminal vesicle invasion and a 9% chance of lymph node involvement.
Conclusion
The use of multivariate analysis using signi®cant predictor variables has augmented our ability to predict pathologic stage. The combination of PSA, Gleason score and clinical stage predicts pathological stage better than any single variable. 4, 5, 7 The construction of clinically useful tables provides readily available information for the prediction of pathologic stage of prostate cancer. Rather than using these statistical probabilities as a strict decisionmaking tool, physicians can use this information to counsel patients regarding the likelihood that a tumor is organ-con®ned and curable with de®nitive local therapy. Patients are then better informed to make decisions about treatment options. It is anticipated that the rational selection of appropriate surgical candidates using these nomograms will likely increase the percentage of organcon®ned tumors and result in improved disease-free survival. 
